iRadimed (NASDAQ:IRMD) CEO Roger Susi Sells 2,500 Shares

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 2,500 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $102.43, for a total transaction of $256,075.00. Following the completion of the sale, the chief executive officer owned 2,240,000 shares of the company’s stock, valued at $229,443,200. This trade represents a 0.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

iRadimed Trading Down 1.3%

Shares of NASDAQ:IRMD traded down $1.34 on Wednesday, hitting $101.46. The company had a trading volume of 41,499 shares, compared to its average volume of 72,331. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of 57.68 and a beta of 1.12. The stock has a 50 day moving average price of $100.44 and a 200 day moving average price of $89.15. iRadimed Corporation has a 1-year low of $47.48 and a 1-year high of $107.90.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.05. The business had revenue of $22.69 million during the quarter, compared to analysts’ expectations of $21.60 million. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. Sell-side analysts anticipate that iRadimed Corporation will post 1.66 earnings per share for the current fiscal year.

iRadimed Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Monday, February 23rd were given a dividend of $0.20 per share. The ex-dividend date was Monday, February 23rd. This represents a $0.80 annualized dividend and a dividend yield of 0.8%. This is a positive change from iRadimed’s previous quarterly dividend of $0.17. iRadimed’s dividend payout ratio (DPR) is 45.71%.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. CWM LLC boosted its stake in iRadimed by 62.2% in the third quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 211 shares during the last quarter. Quarry LP bought a new stake in shares of iRadimed in the 3rd quarter worth approximately $40,000. Farther Finance Advisors LLC lifted its stake in iRadimed by 827.1% in the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 397 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 495 shares during the last quarter. Finally, State of Alaska Department of Revenue bought a new position in iRadimed during the third quarter valued at $47,000. Institutional investors own 92.34% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Lake Street Capital reiterated a “buy” rating and issued a $120.00 target price on shares of iRadimed in a research report on Wednesday, February 11th. Weiss Ratings restated a “buy (b-)” rating on shares of iRadimed in a research note on Monday, December 29th. Finally, Roth Mkm reaffirmed a “buy” rating and set a $120.00 price target on shares of iRadimed in a report on Tuesday, February 10th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $120.00.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.